This is a prospective, single-center randomized trial with three arms, and an allocation
ratio of 1:1:1. The study design is an efficacy study to evaluate the effect of metformin and
coach-directed behavioral weight loss versus self-directed weight loss on insulin-like growth
factor (IGF)-1 and IGF-1 to THE IGFBP-III ratio blood levels after 6 and 12 months of
intervention. The coach-directed Behavioral Weight Loss arm is a web-based remote delivery
and communication system that promotes healthy behavioral changes. The Metformin arm is a
pharmaceutical intervention of oral metformin. This is a secondary prevention study for men
and women who have survived solid malignant tumors
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins